Ryan Haumschild, PharmD, MS, MBA: Hello, and welcome to this AJMC® Peer Exchange program titled “Updates in the Management of Myelodysplastic Syndromes.” I’m Dr Ryan Haumschild, the director of ...
Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN ...
Racial disparities are known to occur with many diseases, including numerous cancers, with Black individuals having lower survival rates than other racial/ethnic groups. However, there have not been ...
A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications. At the start, we’re going to lean heavily on Dr Zeidan because we want to have a good ...
Please provide your email address to receive an email when new articles are posted on . Olutasidenib monotherapy or combination therapy may help certain patients with myelodysplastic syndrome achieve ...
Suleika Jaouad's leukemia experience highlights the importance of mindfulness and support networks in managing the disease.
Hetty Carraway, MD: Hello, and welcome to CURE EXPERT CONNECTIONS®. I’m Dr. Carraway from the Cleveland Clinic, and I’d like to welcome my colleague, Dr. Guillermo Garcia-Manero from The University of ...
The prognostic impact of monocytosis in patients with myelodysplastic syndromes (MDS) is not well-studied and not been clearly defined. Patients with MDS and monocytosis had a shorter overall survival ...
Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas Myelodysplastic syndrome (MDS) classification currently relies mainly on its morphologic features and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback